Lawrence Steinman

See the following -

FDA Clears IND For First Clinical Trial Protocol Developed Using Crowdsourcing

Press Release | Transparency Life Sciences (TLS) | December 18, 2012

Transparency Life Sciences, LLC (TLS), the world's first drug development company based on open innovation, today announced that its Investigational New Drug Application (IND) to assess lisinopril as an adjunctive therapy for multiple sclerosis (MS) has been cleared by the US Food and Drug Administration (FDA). Read More »

Transparency Life Sciences Awarded $1.4 Million NCATS SBIR Grant To Conduct Innovative Trial Of Lisinopril In Multiple Sclerosis

Press Release | Transparency Life Sciences | September 8, 2014

Transparency Life Sciences, LLC (TLS)...today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).

Read More »